Sulzer IntraTherapeutics To Submit PMA For Renal Indication In Early 2002
This article was originally published in The Gray Sheet
Sulzer Medica's IntraTherapeutics unit intends to submit a premarket approval application to FDA for use of its IntraStent DoubleStrut ParaMount XS stent delivery system in the renal artery in the first quarter of 2002.
You may also be interested in...
Renal stent system gains CE mark approval for European marketing. Indicated for the treatment of atherosclerotic disease in the renal arteries, the device has a 6 Fr crossing profile and high radial strength to withstand the elastic recoil found in renal arteries, the company claims. The stent has an unexpanded length of 17 mm and comes in diameters of 5, 6, and 7 mm. The balloon catheter used to deliver the stent comes in lengths of 75 and 120 cm. A version of the system with the same name for the biliary tract is set to be unveiled the week of June 12, according to the company
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.